Abstract
The effect of the two closely related drugs, the sulfone 2-(2-thenyl)sulfonyl-5-bromopyrimidine (NY 4137), and the sulfoxide 2-(2-thenyl)sulfinyl-5-bromopyrimidine (NY 4138), a sulfoxide, on the survival of cells of the human line NHIK 3025 was investigated. Cell survival was measured as the ability of single cells to form macroscopic colonies. Two-hour treatment with 0.012 mM NY 4137 resulted in 50% inactivation. The drug concentration of NY 4138 had to be adjusted about 10 times higher than that of NY 4137 for treatment periods of 2 or 24 h to obtain similar surviving fraction after treatment of asynchronous cells. Treatment of synchronized NHIK 3025 cells with NY 4137 showed that survival varied little with cell age. Following treatment with NY 4138, however, cells were particularly sensitive in G2 and in mitosis. As the survival curves for both drugs display a plateau region, where increasing the drug dose has little or no effect on cell inactivation, the presence of resistant subpopulations of cells is considered. High-performance liquid chromatography of drug solutions in cell culture medium showed that both NY 4137 and NY 4138 bound to, or were metabolized by, medium and/or cell components. The concentration of NY 4137 in cell culture medium, however, was reduced at a higher rate than NY 4138. The half-life of NY 4137 was on the order of 5 h, while the half-life of NY 4138 was over 24 h. These observations correlate well with the relative chemical reactivities for these drugs in nucleophilic displacement reactions.
Similar content being viewed by others
References
Nygaard MEH, Dornish JM, Oftebro R, Undheim K: Effects of the new mitotic inhibitor pyrimidinsulfone NY 4137 on human cells in vitro and on colchicine binding to tubulin. Invest New Drugs 4:221–229, 1986
Pettersen EO, Nome O, Dornish JM, Oftebro R: Mitotic arrest and interphase inhibition induced by the pyrimidine sulfoxide NY 4138. Invest New Drugs 3:245–253, 1985
Madoc-Jones H, Mauro F: Interphase action of vinblastine and vincristine: differences in their lethal action through the mitotic cycle of cultured mammalian cells. J Cellular Physiol 72:185–196, 1968
Nordbye K, Oftebro R: Establishment of four new cell strains from human uterine cervix. I. Exp Cell Res 58:458, 1969
Oftebro R, Nordbye K: Establishment of four new cell strains from human uterine cervix. II. Exp Cell Res 58:459–460, 1969
Puck TT, Cieciura SJ, Fisher HW: Clonal growth in vitro of human cells with fibroblastic morphology. J Exp Med 106:145–165, 1957
Pettersen EO, Bakke O, Lindmo T, Oftebro R: Cell cycle characteristics of synchronized and asynchronous population of human cells and effect of cooling and selected mitotic cells. Cell Tissue Kinet 10:511–522, 1977
Engelberg J: A method of measuring the degree of synchronization of cell populations. Exp Cell Res 23: 218–227, 1961
Bakke O, Pettersen EO: A fast and accurate method for calculating Engelberg's synchronization index. Cell Tissue Kinet 9:389–393, 1976
Gillespie CJ, Chapman JD, Reuvers AP, Dugle DL: The inactivation of Chinese hamster cells by X-rays: Synchronized and exponential cell populations. Radiat Res 64:353–364, 1975
Lindmo T, Pettersen EO: Delay of cell cycle progression after x-irradiation of synchronized populations of human cells (NHIK 3025) in culture. Cell Tissue Kinet 12:43–57, 1979
Lindmo T, Steen HB: Flow-cytometric measurement of the polarization of fluorescence from intracellular fluorescein in mammalian cells. Biophys J 18:173–187, 1977
Benneche T, Gacek MJ, Undheim K: Pyrimidine-2-sulphides and their S-oxides for use in medicine and methods of use therefore, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se. European Pat Appl 0 033 195: 1981
Drewinko B, Roper PR, Barglogie B: Patterns of cell survival following treatment with antitumor agents in vitro. Eur J Cancer 15:93–99, 1979
Wibe E, Oftebro R, Christensen T, Laland SG, Pettersen EO, Lindmo T: Inhibitory effects of the new mitotic inhibitor 5-chloropyrimidin-2-one and of vincristine on human cells in vitro. Cancer Res 38:560–565, 1978
Wibe E, Oftebro R, Laland SG, Pettersen EO, Lindmo T: Cell-cycle inhibitory effects of the mitotic inhibitor NY 3170 on human cells in vitro. Br J Cancer 39:391–397, 1979
Wibe E, Oftebro R: Inactivation by the mitotic inhibitor NY 3170 of human cells in vitro. Br J Cancer 40:222–227, 1979
Wibe E: Age-dependent cell inactivation by vincristine alone or in combination with 1-propargyl-5-chloropyrimidin-2-one. Cancer Res 40:2069–2073, 1980
Author information
Authors and Affiliations
Additional information
Fellow of the Norwegian Cancer Society (Landsforeningen mot Kreft)
Rights and permissions
About this article
Cite this article
Holm Nygaard, M.E., Pettersen, E.O., Dornish, J.M. et al. Inactivation of human cells cultivated in vitro by the new mitotic inhibitors NY 4137 and NY 4138. Invest New Drugs 5, 259–266 (1987). https://doi.org/10.1007/BF00175296
Issue Date:
DOI: https://doi.org/10.1007/BF00175296